BioSpace News Archive

Drug Development

Provention Bio’s Crohn’s Disease Drug Flunks Mid-Stage Trial

The drug showed what the company is calling a “substantial improvement in this symptom-driven score” at the 12-week point, but it did not differentiate from placebo.

October 23, 2019
·
3 min read
·
Mark Terry
How to Show Your Boss You’re Ready for a Promotion

You’ve had your job for a while now. You’ve gotten multiple great reviews. You’ve consistently taken on additional projects and excelled at them. But you have yet to receive a promotion and you’re left wondering “Why?”.

October 23, 2019
·
2 min read
·
Laura Brothers
Drug Development

Good Pharma Scorecard Continues to Boost Clinical Trial Transparency, Analyst Report Shows

Calls for increased transparency in clinical trials have been growing and now many medical journals are requiring authors of submitted papers to disclose whether or not they will be sharing clinical trial results.

October 23, 2019
·
3 min read
·
Alex Keown
Resurgence of Algae in Biotech: From Fuels to Foods

Because algae can grow simply on carbon dioxide and light, they are attractive to companies looking at generating protein from greenhouse gases.

October 23, 2019
·
5 min read
·
David Kirk
Regenstrief and IUPUI researchers use EHRs to identify cancer symptom clusters

Award-winning methodology applicable to symptom clusters in other chronic diseases

October 23, 2019
·
5 min read
Policy

More Breakthroughs in Nanotechnology Could Lead to Improvements in Drug Delivery and Medicine

Researchers have developed a precise and non-toxic nanoscale technology that can deliver oncology drugs directly to cancer cells. The minuscule tubes are called peptoids.

October 23, 2019
·
3 min read
·
Mark Terry
Drug Development

MacroGenics’ Metastatic Breast Cancer Drug Shows Survival Benefits in Phase III Trial

MacroGenics’ metastatic HER2-positive breast cancer treatment margetuximab continues to show promise following a second pre-planned interim overall survival analysis of its Phase III SOPHIA trial.

October 23, 2019
·
2 min read
·
Alex Keown
Drug Development

BreviTest Awarded SBIR Phase II Grant from National Institute on Drug Abuse to Commercialize Device for Rapid Opioid Testing

Houston, TX - BreviTest Technologies has been awarded a $1,500,000 grant from the National Institute on Drug Abuse of the National Institutes of Health to further the commercialization of its point-of-care analyzer for rapid opioid urine testing.

October 23, 2019
·
4 min read
Genetown

New Approaches to Alzheimer’s and Tauopathies: Eikonizo Therapeutics

Janice Kranz, the company’s co-founder and chief executive officer took time to speak with BioSpace about the company and its approach to Alzheimer’s disease and other tauopathies.

October 23, 2019
·
5 min read
·
Mark Terry
Business

Pliant Inks $80 Million+ Deal with Novartis on Liver Disease NASH

The agreement revolves around the development and commercialization of Pliant’s preclinical candidate, PLN-1474, and up to three more integrin targets for liver fibrosis associated with nonalcoholic steatohepatitis.

October 23, 2019
·
3 min read
·
Mark Terry